9 results about "Immune Cell Activation" patented technology

TSLP-TRAPs are a novel class of biologics that have been developed to inhibit the activity of TSLP. By binding to TSLP, TSLP-TRAPS effectively block the interaction between TSLP and its receptor, preventing downstream signaling and immune cell activation. This makes TSLP-TRAPs an attractive therapeutic option for a variety of inflammatory and allergic diseases, including asthma, atopic dermatitis, and eosinophilic esophagitis.

The present invention relates to the use of an antibody or an immunologically active fragment thereof, which specifically binds to integrin β2, as an immuno-oncology agent. The chimeric and humanized antibodies of the present invention specifically bind to integrin β2, which is a tumor-specific antigen and is expressed on the cell membrane of M2 tumor-associated macrophages, and thus can be used as an antibody therapeutic agent for cancer treatment using a cancer cell death mechanism by immune cell activation, an antibody therapeutic agent for cancer treatment, or a cell therapeutic agent for cancer treatment, and can also be used for cancer diagnosis.

The present disclosure provides high-performance immune-activation reporter cell line set. A set of nucleic acid constructs comprising one or more response elements operatively linked to a TATA box motif promoter or a minimal IL-2 promoter are provided. A set of reporter cell lines comprising a polynucleotide sequence encoding a reporter protein under the control of one or more response elements operatively linked to a TATA box motif promoter or a minimal IL-2 promoter is also provided. The provided set of reporter cells enable sensitive and signal-enhanced bioassay performance to reflect and evaluate adaptive immune cell activation / inhibition regulated by the immune receptors CD3, co-stimulatory CD28 and related signaling pathways, and avoid responding bias triggered by particular transcription factor. A controllable engineer method for a functional cell line is further provided.

Compositions and methods for immunotherapy are provided. In some embodiments, a system for immunotherapy includes: a first composition including an engineered polypeptide conjugated to a small molecule activator, where the engineered polypeptide has a molecular weight less than or equal to 10 kDa, and where the engineered polypeptide binds to a marker on a target cell; and a second composition including an immune cell expressing an engineered receptor that binds to the small molecule activator.

This invention provides an immunotherapy regimen for inhibiting tumors, especially solid tumors—combining T cells expressing chimeric CD3e fusion protein with BiTA. The chimeric CD3e fusion protein and BiTA bind to each other, activating T cells and targeting tumor cells. This invention also provides a CAB structure and CAB-edited T cells (CAB-T). BiTA secreted by CAB-T cells in tumor tissue can simultaneously activate CAB-T cells and the endogenous TCRs of non-edited T cells, exerting both CAB-T's own anti-tumor effects and mobilizing the anti-tumor effects of unedited T cells. The chimeric CD3e expressed by CAB-T and BiTA synergistically exert anti-tumor effects: the activation of chimeric CD3e depends on BiTA secreted by CAB-T, and the secretion of BiTA further stimulates CAB-T to release more BiTA by activating chimeric CD3e; the small amount of BiTA released by CAB-T in tumor tissue can stimulate CAB-T to release more BiTA by activating chimeric CD3e, achieving tumor-preferred immune cell activation and anti-tumor effects, ensuring the safety advantage of CAB-T in clinical applications.

The present application provides a compound useful as an effective ingredient of a therapeutic drug composition for a cancer associated with immune cell activation or a cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy. The present inventors have researched a compound useful as an effective ingredient of a therapeutic drug composition for a cancer associated with immune cell activation or a cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy, and have confirmed that a heteroaryl formamide compound has DGKζ (DGKzeta) inhibitory action, thereby completing the present application. The heteroaryl formamide compound of the present application has DGKζ inhibitory action, and can be used as a therapeutic agent for a cancer associated with immune cell activation or a cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy.

This invention relates to proteins targeting B7H3 and methods of using them. Multispecific B7H3-targeting compounds and methods of using them are provided. These multispecific compounds include bispecific and trispecific targeting proteins. The bispecific targeting protein includes a B7H3 targeting domain and an immune cell binding domain; the trispecific targeting protein includes a B7H3 targeting domain, an immune cell binding domain, and an immune cell activation domain. These methods of use include methods for inducing NK-mediated cell killing, methods for inducing NK cell proliferation in vivo, and methods for treating cancer.

Provided herein are, inter alia, improved materials and methods for obtainment and use of immune cells (e.g., T cells). In particular, the present disclosure provides improved materials and methods of ex vivo immune cell activation, immune cell expansion, and / or enrichment of immune cells, immune cell subsets, and more specifically Vγ9Vδ2 cells. The present disclosure further provides isolated or purified populations of such Vγ9Vδ2 cells, and the ex vivo and in vivo uses thereof. Also provided herein, in various embodiments, are compositions comprising such improved cells, including the isolated or purified populations of such produced Vγ9Vδ2 cells. CAR cells, and the like, and uses of such compositions and cells in treating a subject in need thereof having, for example, a disease or a disorder.

This invention discloses an injectable composite hydrogel adjuvant, its preparation method, and its application. The composite hydrogel adjuvant is formed by conjugating the TLR receptor 7 agonist Gardimquid to chitosan oligosaccharide, and then adding the Gardimquid-conjugated chitosan oligosaccharide to an oxidized hyaluronic acid solution, forming a stable gel through chemical cross-linking. This composite hydrogel adjuvant is loaded with calcium phosphate-mineralized type O foot-and-mouth disease virus-like particles to form a hydrogel vaccine. Experimental results show that the vaccine has excellent biocompatibility, recruiting 16.12% dendritic cells and 9.62% macrophages (antigen-presenting cells), and has the ability to enhance antigen migration and uptake, and promote immune cell activation. Furthermore, it can induce sustained and potent levels of specific antibodies and cellular immunity, and maintain immune memory for 20 weeks. This invention provides an effective technical means to improve the duration of immunity from foot-and-mouth disease virus-like particles, enhance the immunization effect, and achieve single-dose immunization.